Guerra Pan Advisors LLC Has $274,000 Position in Pfizer Inc. (NYSE:PFE)

Guerra Pan Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,511 shares of the biopharmaceutical company’s stock after selling 640 shares during the period. Guerra Pan Advisors LLC’s holdings in Pfizer were worth $274,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Moneta Group Investment Advisors LLC grew its position in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter valued at $3,150,472,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after purchasing an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pfizer in the 1st quarter valued at $311,238,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.05 during mid-day trading on Tuesday, reaching $25.86. 11,071,321 shares of the company’s stock traded hands, compared to its average volume of 42,308,930. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.33. The firm has a 50 day moving average price of $27.27 and a two-hundred day moving average price of $28.84. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market capitalization of $146.43 billion, a PE ratio of 71.86, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the firm posted $1.14 EPS. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.